INM
Price:
$4.66
Market Cap:
$3.35M
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosyn...[Read more]
Industry
Biotechnology
IPO Date
2014-05-05
Stock Exchange
NASDAQ
Ticker
INM
According to InMed Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 631.55M. This represents a change of -93.99% compared to the average of 10.50B of the last 4 quarters.
The mean historical Enterprise Value of InMed Pharmaceuticals Inc. over the last ten years is 568.48M. The current 631.55M Enterprise Value has changed 11.01% with respect to the historical average. Over the past ten years (40 quarters), INM's Enterprise Value was at its highest in in the June 2024 quarter at 38.33B. The Enterprise Value was at its lowest in in the June 2018 quarter at -18350271.00.
Average
568.48M
Median
308.32M
Minimum
32.55M
Maximum
2.13B
Discovering the peaks and valleys of InMed Pharmaceuticals Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 385.08%
Maximum Annual Enterprise Value = 2.13B
Minimum Annual Increase = -70.83%
Minimum Annual Enterprise Value = 32.55M
Year | Enterprise Value | Change |
---|---|---|
2024 | 32.55M | -11.74% |
2023 | 36.87M | -70.83% |
2022 | 126.39M | -70.06% |
2021 | 422.21M | -51.69% |
2020 | 874.03M | -24.35% |
2019 | 1.16B | -45.84% |
2018 | 2.13B | 262.47% |
2017 | 588.51M | 385.08% |
2016 | 121.32M | -37.60% |
2015 | 194.44M | -53.54% |
The current Enterprise Value of InMed Pharmaceuticals Inc. (INM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
65.27M
5-year avg
298.41M
10-year avg
568.48M
InMed Pharmaceuticals Inc.’s Enterprise Value is greater than Quoin Pharmaceuticals, Ltd. (-162664.00), greater than Allarity Therapeutics, Inc. (-11495345.00), greater than Kiromic BioPharma, Inc. (13.48M), greater than Virax Biolabs Group Limited (5.36M), greater than Biodexa Pharmaceuticals Plc (-2820215.62), greater than SeaStar Medical Holding Corporation (7.07M), greater than Virios Therapeutics, Inc. (-2813681.00), greater than ZyVersa Therapeutics, Inc. (2.53M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), greater than Revelation Biosciences, Inc. (-3300245.00), greater than Palisade Bio, Inc. (-4438971.00), greater than Bright Minds Biosciences Inc. (337.02M), greater than Tonix Pharmaceuticals Holding Corp. (15.97M), greater than Immix Biopharma, Inc. (30.53M), greater than Phio Pharmaceuticals Corp. (-2783607.00), greater than 180 Life Sciences Corp. (4.73M), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than Sigilon Therapeutics, Inc. (42.21M), greater than NovaBay Pharmaceuticals, Inc. (3.81M), greater than GeoVax Labs, Inc. (19.24M),
Company | Enterprise Value | Market cap |
---|---|---|
-162664.00 | $2.95M | |
-11495345.00 | $5.63M | |
13.48M | $1.69M | |
5.36M | $8.73M | |
-2820215.62 | $2.32M | |
7.07M | $9.15M | |
-2813681.00 | $206.50K | |
2.53M | $2.65M | |
-907921.00 | $2.50M | |
-3300245.00 | $3.24M | |
-4438971.00 | $3.24M | |
337.02M | $245.49M | |
15.97M | $35.51M | |
30.53M | $49.14M | |
-2783607.00 | $2.61M | |
4.73M | $4.45M | |
-2504975.00 | $100.08K | |
42.21M | $56.22M | |
3.81M | $3.33M | |
19.24M | $27.84M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InMed Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like InMed Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is InMed Pharmaceuticals Inc.'s Enterprise Value?
What is the highest Enterprise Value for InMed Pharmaceuticals Inc. (INM)?
What is the 3-year average Enterprise Value for InMed Pharmaceuticals Inc. (INM)?
What is the 5-year average Enterprise Value for InMed Pharmaceuticals Inc. (INM)?
How does the current Enterprise Value for InMed Pharmaceuticals Inc. (INM) compare to its historical average?